Bausch Health Companies (BHC) Non-Current Debt (2009 - 2026)
Bausch Health Companies (BHC) reported Non-Current Debt of $20.8 billion for Q1 2026, down 3.47% on a YoY basis from $21.5 billion in Q1 2025, and little changed sequentially from $20.8 billion in Q4 2025.
Bausch Health Companies (BHC) Non-Current Debt (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Non-Current Debt data on file, last reported at $20.8 billion in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Debt fell 3.47% year-over-year to $20.8 billion; the trailing twelve-month figure through Mar 2026 stood at $20.8 billion (down 3.47% YoY), and the FY2025 full-year result was $20.8 billion, up 9.9% from the prior year.
- Non-Current Debt held at $20.8 billion in Q1 2026, from $20.8 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $23.2 billion in Q1 2022 to a low of $18.9 billion in Q4 2024.
- A 5-year average of $21.2 billion and a median of $21.2 billion in 2024 frame the typical range for Non-Current Debt.
- Across the five-year window, Non-Current Debt decreased 13.66% in 2024 and climbed 9.9% in 2025, its largest moves.
- Tracing BHC's Non-Current Debt over 5 years: stood at $20.8 billion in 2022, then climbed by 5.64% to $21.9 billion in 2023, then declined by 13.66% to $18.9 billion in 2024, then climbed by 9.9% to $20.8 billion in 2025, then dropped by 0.25% to $20.8 billion in 2026.
- Business Quant data shows BHC's Non-Current Debt at $20.8 billion in Q1 2026, $20.8 billion in Q4 2025, and $20.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | 20.76 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.76 Bn |
| Dec 31, 2025 | 20.82 Bn |
| Sep 30, 2025 | 20.46 Bn |
| Jun 30, 2025 | 21.74 Bn |
| Mar 31, 2025 | 21.51 Bn |
| Dec 31, 2024 | 18.94 Bn |
| Sep 30, 2024 | 21.51 Bn |
| Jun 30, 2024 | 21.21 Bn |
| Mar 31, 2024 | 21.54 Bn |
| Dec 31, 2023 | 21.94 Bn |
| Sep 30, 2023 | 22.43 Bn |
| Jun 30, 2023 | 20.11 Bn |
| Mar 31, 2023 | 20.65 Bn |
| Dec 31, 2022 | 20.77 Bn |
| Sep 30, 2022 | 20.80 Bn |
| Jun 30, 2022 | 21.81 Bn |
| Mar 31, 2022 | 23.17 Bn |
| Dec 31, 2021 | 22.65 Bn |
| Sep 30, 2021 | 22.36 Bn |
| Jun 30, 2021 | 23.44 Bn |